Analysis of Amlodipine and Losartan Potassium


Both amlodipine and losartan potassium are sold worldwide as drug for hypertension. Combination drug containing the two is also studied.

In this note, chromatograms of simultaneous analysis of amlodipine and losartan were shown under two different HPLC condition using Inertsil ODS-4. Condition 1 is based on the assay of amlodipine besylate tablets of United States Pharmacopeia (USP). Condition 2 is a method using eluent of simpler composition. Application for each individual ingredient is also shown in LC technical note No.98 and No.126.

Chemical Structure Amlodipine Besylate Structures are created using Chemistry 4-D Draw which is provided by Cheminnovation Software, Inc.

HPLC Condition 1

Standard Solution



Conditions

Column : Inertsil ODS-4 HP

 $(3 \mu m, 50 \times 4.6 \text{ mm I.D.})$

Cat. No. : 5020-14068

Eluent : A) CH₃OH

B) CH₃CN

C) 0.7 % Triethylamine

(pH 3.0, H₃PO₄)

A/B/C =7/3/10, v/v/v

Flow rate : 1.0 mL/min


Column Temp. : 25 °C

Detection : UV 237 nm

Injection Vol. : 5 uL

Tablet Sample

The sample concentration was adjusted to 5 mg/L and 50 mg/L as amlodipine and losartan potassium, respectively.



Example of Pretreatment Method for Tablet Sample

Sample

Grind tablet into powder

Weigh the powder equivalent to one tablet

Extraction

Add diluent*

Sonication extraction for 5 min

Make up to 100 mL with diluent

Filtration

0.45 µm membrane filter

Dilution

Adjust the concentration of amlodipine and losartan potassium to 5 mg/L and 50 mg/L, respectively, by adding diluent.


HPLC

* Diluent: eluent




HPLC Condition 2

Standard Solution



Tablet Sample

The sample concentration was adjusted to 5 mg/L and 50 mg/L as amlodipine and losartan potassium, respectively.



Conditions

Column : Inertsil ODS-4 HP

 $(3 \mu m, 50 \times 4.6 \text{ mm I.D.})$

Cat. No. : 5020-14068

Eluent : A) CH₃CN

B) 0.02 % Triethylamine (pH

2.5, H₃PO₄)

A/B = 35/65, v/v


Flow rate : 1.0 mL/min

Column Temp. : 30 °C

Detection : UV 226 nm

Injection Vol. : 5 uL

Example of Pretreatment Method for Tablet Sample



GL Sciences disclaims any and all responsibility for any injury or damage which may be caused by this data directly or indirectly. We reserve the right to amend this information or data at any time and without any prior announcement.

GL Sciences, Inc. Japan

22-1 Nishishinjuku 6-Chome Shinjuku-ku, Tokyo, 163-1130, Japan Phone: +81-3-5323-6620

Fax: +81-3-5323-6621
Email: world@gls.co.jp
Web: www.glsciences.com

GL Sciences B.V.

De Sleutel 9 5652 AS Eindhoven The Netherlands Phone: +31 (0)40 254 95 31

Email: <u>info@glsciences.eu</u>
Web: www.glsciences.eu

GL Sciences (ShangHai) Ltd.

Tower B, Room 2003, Far East International Plaza, NO,317 Xianxia Road, Changning District. Shanghai. China P.C. 200032

Phone: +86 (0)21-6278-2272

Email: contact@glsciences.com.cn

Web: www.glsciences.com.cn

GL Sciences, Inc. USA

4733 Torrance Blvd. Suite 255 Torrance, CA 90503 Phone: 310-265-4424 Fax: 310-265-4425

Email: info@glsciencesinc.com
Web: www.glsciencesinc.com

International Distributors

Visit our Website at:

https://www.glsciences.com/company/distributor.html

